Renasant Bio
ApprovedAt Renasant Bio, we are pioneering a new approach to treating autosomal dominant polycystic kidney disease (ADPKD), a devastating genetic disorder with no disease-modifying therapies and the leading genetic cause of end-stage renal failure. Our mission is to develop small molecule correctors and potentiators that target the root cause of the disease, restoring the function of polycystin 1 and 2 (PC1/2) to halt disease progression.
About
At Renasant Bio, we are pioneering a new approach to treating autosomal dominant polycystic kidney disease (ADPKD), a devastating genetic disorder with no disease-modifying therapies and the leading genetic cause of end-stage renal failure. Our mission is to develop small molecule correctors and potentiators that target the root cause of the disease, restoring the function of polycystin 1 and 2 (PC1/2) to halt disease progression.
Company Info
Contact
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile